A randomized phase I pharmacokinetic trial comparing the potential biosimilar adalimumab (CinnoRA ®) with the reference product (Humira®) in healthy volunteers.

Conclusions: The results clearly showed the pharmacokinetic similarity of the biosimilar adalimumab to the originator. CinnoRA® was safe and well-tolerated in healthy volunteers, with no significant differences in safety from the reference product. PMID: 31985294 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31985294?dopt=Abstract

Source: Expert Opinion on Investigational Drugs - January 29, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research